CYP2C19 and Hepatic failure: The results of a dosing regimen optimization based on MonteCarlo simulation showed that the maintenance dose of VRZ should be decreased to less than 50% in individuals with mild to moderate hepatic insufficiency with extensive CYP2C19 metabolism and o 1/4 in individuals with moderate to severe hepatic insufficiency (Ren et al., 2019).